The leucovorin (folinic acid) controversy in autism centers on whether folinic acid is an effective and appropriate treatment for some children with autism spectrum disorder (ASD), how broadly it should be used, and whether the supporting evidence justifies clinical adoption and marketing.
Background
Folinic acid (often called leucovorin) is an active form of folate used medically for folate rescue and in chemotherapy. Interest in folinic acid for ASD stems from two related biological observations: (1) some children with ASD have impaired transport of folate into the brain, often associated with autoantibodies to the folate receptor alpha (FRAA), producing a syndrome called cerebral folate deficiency (CFD); (2) folate is crucial for neurodevelopment, methylation, and neurotransmitter synthesis. Small studies proposed that folinic acid supplementation might bypass transport problems and improve symptoms in children with ASD, particularly those with FRAA-positive status.
Clinical evidence review indicates that early open-label reports and small randomized controlled trials (RCTs) have suggested possible benefit of high-dose folinic acid on language and communication in subgroups of children with ASD, especially those testing positive for FRAAs.
The most-cited RCTs reported improvements in verbal communication and global functioning over several months in FRAA-positive participants. However, sample sizes were small, effect sizes varied, and some trials had methodological limitations (short duration, heterogeneous participants, variable dosing, and reliance on parent-reported outcomes). Subsequent attempts to replicate findings have produced mixed results. Meta-analytic summaries note potential benefit for a subset (FRAA-positive) but emphasize low-to-moderate quality evidence and the need for larger, well-controlled trials.
Controversial aspects
1. Broad vs. targeted use: Targeted screening (FRAA testing) and folinic acid supplementation for FRAA-positive children has been advocated for; critics warn against indiscriminate use in all children with ASD given the limited and inconsistent data.
2. Testing validity and accessibility: FRAA assays are available commercially but vary in reliability, and interpretation can be challenging. Insurance coverage for testing and for prolonged high-dose folinic acid therapy has been inconsistent.
3. Dosing and safety: Trials used relatively high folinic acid doses (often 0.5-2 mg/kg/day or fixed high doses). Short-term safety appears acceptable in most studies, but long-term safety data are limited. Concerns include masking B12 deficiency, altering methylation pathways, and unknown neurodevelopmental effects over years.
4. Conflicts of interest and commercialization: The market for testing and supplements has grown, raising concerns about profit motives influencing promotion before definitive evidence is established.
5. Expectation management and ethics: Families facing limited effective therapies for core ASD symptoms may be eager to try promising interventions. Ethical tensions arise between hope-driven demand and the responsibility to avoid unproven, potentially costly or risky treatments.
6. Policy and research implications The controversy underscores the need for: larger, multisite RCTs stratified by FRAA status; standardized, validated FRAA testing; clear dosing and monitoring guidelines; and long-term safety surveillance. It also highlights broader issues in ASD care – how to responsibly translate research findings into practice, how to regulate and reimburse off-label or adjunctive treatments, and how to communicate uncertain evidence to families.
Decision-making
Leucovorin is not a benign treatment intervention. There are potential adverse effects of pruritus, urticaria, dyspnea, rigors, impaired thermoregulation, and life-threatening allergic reaction (anaphylaxis).
The American Academy of Pediatrics (AAP) does not recommend the routine use of leucovorin (folinic acid) for autistic children. As per the AAP website, “Larger, well-controlled clinical trials are needed to determine whether leucovorin is a safe and effective option for the broader autistic pediatric population.”
On March 10, 2026, the US Food and Drug Administration (FDA) provided approval for use of leucovorin in the treatment of cerebral folate deficiency in adult and pediatric patients who have a confirmed variant in the folate receptor 1 gene (CFD-FOLR1).
There is no current FDA approval for the use in autistic patients in the absence of having the confirmed variant in the folate receptor 1 gene (CFD-FOLR1).
In summary, folinic acid shows biologic plausibility and preliminary evidence of benefit for a subset of children with ASD (notably those with FRAAs), but current data are insufficient for universal endorsement. Targeted testing and cautious, monitored use within research or informed clinical contexts are the most widely recommended approaches until more definitive trials clarify efficacy, optimal dosing, and safety.
References
- Rossignol DA, Frye RE. Cerebral Folate Deficiency, Folate Receptor Alpha Autoantibodies and Leucovorin (Folinic Acid) Treatment in Autism Spectrum Disorders: A Systematic Review and Meta-Analysis. J Pers Med. 2021 Nov 3;11(11):1141. doi: 10.3390/jpm11111141. Erratum in: J Pers Med. 2022 Apr 29;12(5):721. doi: 10.3390/jpm12050721.
- Frye RE, McCarty PJ, Werner BA, Scheck AC, Collins HL, Adelman SJ, Rossignol DA, Quadros EV. Binding Folate Receptor Alpha Autoantibody Is a Biomarker for Leucovorin Treatment Response in Autism Spectrum Disorder. J Pers Med. 2024 Jan 1;14(1):62. doi: 10.3390/jpm14010062.
- Frye RE, Lane A, Worner A, Werner BA, McCarty PJ, Scheck AC, Collins HL, Adelman SJ, Quadros EV, Rossignol DA. The Soluble Folate Receptor in Autism Spectrum Disorder: Relation to Autism Severity and Leucovorin Treatment. J Pers Med. 2022 Dec 8;12(12):2033. doi: 10.3390/jpm12122033.
- Frye RE, Rossignol DA, Scahill L, McDougle CJ, Huberman H, Quadros EV. Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder. Semin Pediatr Neurol. 2020 Oct;35:100835. doi: 10.1016/j.spen.2020.100835. Epub 2020 Jun 25.
- Howard C, Mekhail J, Ravikoff LM, Milanaik R. Clinical concerns and considerations for leucovorin use in autism spectrum disorder. Curr Opin Pediatr. 2026 Apr 1;38(2):207-211. doi: 10.1097/MOP.0000000000001547. Epub 2026 Feb 2.
